NADPH Oxidase Inhibitors: New Antihypertensive Agents?
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
NADPH oxidases have recently been shown to contribute to the pathogenesis of hypertension. The development of specific inhibitors of these enzymes has focused attention on their potential therapeutic use in hypertensive disease. Two of the most specific inhibitors, gp91ds-tat and apocynin, have been shown to decrease blood pressure in animal models of hypertension. Other inhibitors, including diphenylene iodonium, aminoethyl benzenesulfono fluoride, S17834, PR39, protein kinase C inhibitors, and VAS2870, have shown promise in vitro, but their in vivo specificity, pharmacokinetics, and effectiveness in hypertension remains to be determined. Of importance, the currently available antihypertensive agents angiotensin-converting enzyme inhibitors and angiotensin receptor blockers also effectively inhibit NADPH oxidase activation. Similarly, the cholesterol-lowering agents, statins, have been shown to attenuate NADPH oxidase activation. Although, antioxidants act to scavenge the reactive oxygen species produced by these enzymes, their effectiveness is limited. Targeting NADPH homologues may have a distinct advantage over current therapies because it would specifically prevent the pathophysiological formation of reactive oxygen species that contributes to hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NAD(P)H Oxidase: Role in Cardiovascular Biology and Disease
Griendling, K. K., Sorescu, D., & Ushio-Fukai, M. (2000) · Circulation Research · doi:10.1161/01.res.86.5.494 · Cited by 2,886
Self-citationVitamin E Supplementation and Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420302 · Cited by 1,957
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases
Martyn, K. D., Frederick, L. M., von Loehneysen, K., Dinauer, M. C., & Knaus, U. G. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.023 · Cited by 783
The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases
Cai, H., Griendling, K. K., & Harrison, D. G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00233-5 · Cited by 687
Self-citationMollnau, H., Wendt, M., Szöcs, K., Lassègue, B., Schulz, E., Oelze, M., Li, H., Bodenschatz, M., August, M., Kleschyov, A. L., et al. (2002) · Circulation Research · doi:10.1161/01.res.0000012569.55432.02 · Cited by 676 · cited 1×
“In Ang II-infused rats, the PKC inhibitor chelerythrine (5 mg/kg/d) inhibits increased superoxide production and NADPH oxidase subunit upregulation.(80) In a human study with the selective PKCb inhibitor LY333531 (ruboxistaurin mesylate, RBX) at 32 mg/d, endothelial dysfunction was inhibited, possibly through inhibiti…”
BackgroundSelf-citationTouyz, R. M., Chen, X., Tabet, F., Yao, G., He, G., Quinn, M. T., Pagano, P. J., & Schiffrin, E. L. (2002) · Circulation Research · doi:10.1161/01.res.0000020404.01971.2f · Cited by 590 · cited 1×
“It has also been used effectively in human VSMCs to inhibit superoxide production.(52) Apocynin has shown promising application in animal studies of hypertension and other cardiovascular diseases.”
Backgroundp22phox mRNA Expression and NADPH Oxidase Activity Are Increased in Aortas From Hypertensive Rats
Fukui, T., Ishizaka, N., Rajagopalan, S., Laursen, J. B., Capers, Q., Taylor, W. R., Harrison, D. G., de Leon, H., Wilcox, J. N., & Griendling, K. K. (1997) · Circulation Research · doi:10.1161/01.res.80.1.45 · Cited by 553
Self-citationCross, A. R., & Jones, O. T. G. (1986) · Biochemical Journal · doi:10.1042/bj2370111 · Cited by 551 · cited 1×
“DPI inhibits oxidase activity in cell free assays of human and pig neutrophils (10 mM) as well as in whole cells (20 mM).(68,69) DPI has an estimated LD50 of 6 mg/kg in rats and 8 mg/kg in mice.”
BackgroundNox1 Is Involved in Angiotensin II–Mediated Hypertension: A Study in Nox1-Deficient Mice
Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., Takai, S., Yamanishi, K., Miyazaki, M., Matsubara, H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.573709 · Cited by 470 · cited 2×
“Ang II is a potent stimulus for NADPH oxidase activity in all cells of the vasculature, and for this agent more than any other, its hypertensive effects have been shown to be mediated in part by the resulting ROS generation.(29,30) In addition, Ang II is a mediator of many other hypertensive stimuli.”
BackgroundDikalova, A., Clempus, R., Lassègue, B., Cheng, G., McCoy, J., Dikalov, S., Martin, A. S., Lyle, A., Weber, D. S., Weiss, D., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.538934 · Cited by 438 · cited 2×
“Ang II is a potent stimulus for NADPH oxidase activity in all cells of the vasculature, and for this agent more than any other, its hypertensive effects have been shown to be mediated in part by the resulting ROS generation.(29,30) In addition, Ang II is a mediator of many other hypertensive stimuli.”
BackgroundSelf-citationTENFREYHAUS, H., HUNTGEBURTH, M., WINGLER, K., SCHNITKER, J., BAUMER, A., VANTLER, M., BEKHITE, M., WARTENBERG, M., SAUER, H., & ROSENKRANZ, S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.022 · Cited by 259 · cited 3×
“6 mM in cell-free systems using neutrophil membrane and cytosol, and an IC50 of 2 mM in HL-60 cells.(47) In both VSMCs and endothelial cells, VAS2870 is able to inhibit ROS production in response to PDGF and oxLDL without affecting basal ROS production.”
BackgroundMethodDeLeo, F. R., Yu, L., Burritt, J. B., Loetterle, L. R., Bond, C. W., Jesaitis, A. J., & Quinn, M. T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7110 · Cited by 150
Cited by
Cellular death, reactive oxygen species (ROS) and diabetic complications
Volpe, C. M. O., Villar-Delfino, P. H., dos Anjos, P. M. F., & Nogueira-Machado, J. A. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0135-z · Cited by 1,166
Vitamins C and E: Beneficial effects from a mechanistic perspective
Traber, M. G., & Stevens, J. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.017 · Cited by 1,076
Mechanisms of oxidative stress in plants: From classical chemistry to cell biology
Demidchik, V. (2015) · Environmental and Experimental Botany · doi:10.1016/j.envexpbot.2014.06.021 · Cited by 944
NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets
Zhang, Y., Murugesan, P., Huang, K., & Cai, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0260-8 · Cited by 534
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
Metadata
- Authors
- Williams, H. C., & Griendling, K. K.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2007-07
- Volume
- 50
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2070926750
- Cited by
- 147
- References
- 13
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.